Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comprehensive characterization of the epigenetic landscape in Multiple Myeloma.
Alaterre E, Ovejero S, Herviou L, de Boussac H, Papadopoulos G, Kulis M, Boireau S, Robert N, Requirand G, Bruyer A, Cartron G, Vincent L, Martinez AM, Martin-Subero JI, Cavalli G, Moreaux J. Alaterre E, et al. Theranostics. 2022 Jan 16;12(4):1715-1729. doi: 10.7150/thno.54453. eCollection 2022. Theranostics. 2022. PMID: 35198065 Free PMC article.
Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study.
Gagez AL, Paul F, Alaterre E, Gouilleux-Gruart V, Tuaillon E, Lepretre S, Ternant D, Letestu R, Moreaux J, Cartron G. Gagez AL, et al. Among authors: alaterre e. Leuk Lymphoma. 2021 Dec;62(13):3160-3169. doi: 10.1080/10428194.2021.1955879. Epub 2021 Nov 22. Leuk Lymphoma. 2021. PMID: 34806520
PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma.
Haas M, Caron G, Chatonnet F, Manenti S, Alaterre E, Devin J, Delaloy C, Bertolin G, Viel R, Pignarre A, Llamas-Gutierrez F, Marchalot A, Decaux O, Tarte K, Delpy L, Moreaux J, Fest T. Haas M, et al. Among authors: alaterre e. Blood. 2022 Apr 14;139(15):2316-2337. doi: 10.1182/blood.2021014011. Blood. 2022. PMID: 35108359 Free article.
The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance.
Ovejero S, Viziteu E, Dutrieux L, Devin J, Lin YL, Alaterre E, Jourdan M, Basbous J, Requirand G, Robert N, de Boussac H, Seckinger A, Hose D, Vincent L, Herbaux C, Constantinou A, Pasero P, Moreaux J. Ovejero S, et al. Among authors: alaterre e. Front Immunol. 2022 Dec 9;13:983181. doi: 10.3389/fimmu.2022.983181. eCollection 2022. Front Immunol. 2022. PMID: 36569948 Free PMC article.
EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.
Chemlal D, Varlet E, Machura A, Ovejero S, Requirand G, Robert N, Cartron G, Alaterre E, Bret C, Vincent L, Herbaux C, Cavalli G, Bruyer A, De Boussac H, Moreaux J. Chemlal D, et al. Among authors: alaterre e. Leukemia. 2023 Sep;37(9):1925-1928. doi: 10.1038/s41375-023-01983-0. Epub 2023 Aug 2. Leukemia. 2023. PMID: 37532787 Free PMC article. No abstract available.
16 results